Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Association Jean Baptiste Desbrest | OTHER |
| AstraZeneca | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
The objectives of this study are to use the Delphi method to assemble an expert panel representing innovation in asthma treatment, to collect freely suggested recommendation statements concerning OCS tapering (and sub-topics) among severe asthma patients from this panel for peer evaluation, and finally to determine the level of consensus for each statement from the panel as a whole.
A series of anonymous questionnaires will be administered to a panel of experts. Each questionnaire administered results in a body of information that is re-presented to the experts before performing the next round. Initial brainstorming questionnaires are open in nature, and are used to generate statements that individual experts would like to see evaluated by their peers. Subsequent ranking questionnaires require that each expert rank each statement according to a pre-defined likert scale. Serial ranking questionnaires are administered electronically and continue until stopping rules are met, or the maximum number of allowed rounds is achieved (capped at three rounds for the present study).
Experts are recruited by invitation or response to open call (see eligibility criteria and url at the end of this declaration.)
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| The expert panel | Participation in this study will be proposed to a group of experts, including pulmonologists, endocrinologists, allergists, paediatricians and rheumatologists. Additionally, patient advocacy organization representatives will also be invited. Experts meeting eligibility criteria (see section below) are invited to participate. Further details are available via the URL link at the end of this declaration. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Brainstorming 1 | Other | Expert recommendation statements will be collected for peer evaluation. |
|
| Measure | Description | Time Frame |
|---|---|---|
| The number of recommendation statements achieving positive consensus | When >= 70% of the expert panel indicates either "agree" or "strongly agree" for a given statement, a positive consensus has been met. | Approximately month 5 |
| The number of recommendation statements achieving negative consensus | When >= 70% of the expert panel indicates either "disagree" or "strongly disagree" for a given statement, a positive consensus has been met. | Approximately month 5 |
| The number of recommendation statements achieving consensus for neutrality | When >= 70% of the expert panel indicates "neutral" for a given statement, a consensus for neutrality has been met. | Approximately month 5 |
| Measure | Description | Time Frame |
|---|---|---|
| The number of statements meeting the stopping rule after ranking round 1. | When >= 70% of the expert panel indicates the same score for a given statement, no subsequent rounds of ranking for that statement will be performed. | Approximately month 5 |
| The number of statements meeting the stopping rule after ranking round 2. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
The expert panel may include pulmonologists, endocrinologists, allergists, paediatricians and rheumatologists. Additionally, patient advocacy organization representatives will also be invited. Potential experts may respond to open invitation via the link at the end of this study registration.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Carey Suehs, PhD | Association Jean Baptiste Desbrest | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Carey Suehs | Montpellier | 34295 | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33722424 | Background | Suehs CM, Bourdin A. Tapering of Oral Corticosteroids for the Treatment of Asthma. Arch Bronconeumol (Engl Ed). 2021 Feb 17:S0300-2896(21)00054-5. doi: 10.1016/j.arbres.2021.01.029. Online ahead of print. No abstract available. English, Spanish. | |
| 33112646 | Result | Suehs CM, Menzies-Gow A, Price D, Bleecker ER, Canonica GW, Gurnell M, Bourdin A; Oral Corticosteroids Tapering Delphi Expert Panel. Expert Consensus on the Tapering of Oral Corticosteroids for the Treatment of Asthma. A Delphi Study. Am J Respir Crit Care Med. 2021 Apr 1;203(7):871-881. doi: 10.1164/rccm.202007-2721OC. |
| Label | URL |
|---|---|
| Description The OCS Tapering Delphi study on the Open Science Framework. | View source |
Not provided
Anonymized data will be shared on an appropriate public platform at the time of publication.
Anonymized data will be shared on an appropriate public platform at the time of publication.
Not provided
Not provided
| ID | Term |
|---|---|
| D001249 | Asthma |
| ID | Term |
|---|---|
| D001982 | Bronchial Diseases |
| D012140 | Respiratory Tract Diseases |
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Ranking Round 1 | Other | Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree. |
|
| Ranking Round 2 | Other | Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree. |
|
| Ranking Round 3 | Other | Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree. |
|
When >= 70% of the expert panel indicates the same score for a given statement, no subsequent rounds of ranking for that statement will be performed. |
| Approximately month 5 |
| The number of statements meeting the stopping rule after ranking round 3. | When >= 70% of the expert panel indicates the same score for a given statement, no subsequent rounds of ranking for that statement will be performed. | Approximately month 5 |
| D012130 |
| Respiratory Hypersensitivity |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |